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PSY12
REAL-LIFE BUDGET IMPACT (BI) OF PARENTERAL IRON TREATMENT 
OF IRON DEFICIENCY ANEMIA/SYNDROME (IDA/IDS) IN SWITZERLAND
Brock E1, Braunhofer P2, Troxler J3, Schneider H1
1HealthEcon AG, Basel, Switzerland; 2Vifor Pharma International, Glattbrugg, Switzerland; 
3Vifor AG, Villars-sur-Glane, Switzerland
OBJECTIVES: IDA/IDS is common in pregnancy, postpartum, inﬂ ammatory bowel 
disease, chronic kidney disease, chronic heart failure, menorrhagia/hypermenorrhagia, 
cancer and following surgery. We estimate the BI associated with substituting iron 
sucrose (standard) with ferric carboxymaltose (new treatment), which allows for the 
application of higher dosages in a shorter time. The analysis adopted the perspective 
of the Swiss mandatory health insurance (MHI) covering the above indications and is 
based on real-life data to verify the hypothetical BI estimated prior to launch. 
METHODS: Resource use (no. of patients, dosage per application, no. of applications) 
was based on recent primary data (Polyquest Prescriber Analysis, Anemia Patient 
Record Study in Switzerland). Personnel costs were estimated using the Swiss Tarmed 
fee-for-service reimbursement system. Drug costs and costs of materials used were 
based on ofﬁ cial tariffs (Spezialitätenliste, MiGeL). Real-life IMS sales data of both 
products were used to verify the BI model. RESULTS: Ferric carboxymaltose was 
associated with cost savings of 30–44% compared to iron sucrose based on costs of 
CHF 101/ 210/ 420 and CHF 144/ 375/ 721 per 200/ 500/ 1000 mg treatment cycle, 
respectively. This leads to cost savings of CHF 15–33 million per year to the Swiss 
MHI across all indications in the ﬁ rst 3 years post-launch, due to reductions in person-
nel costs. Ferric carboxymaltose was shown to be cost-saving in all indications except 
dialysis (due to ﬂ at-fee reimbursement). Sensitivity analyses showed the amount of 
cost savings to be sensitive to changes in the number of inpatients (10–20% of total) 
treated with intravenous iron (due to ﬂ at-fee reimbursement). CONCLUSIONS: Treat-
ing IDA/IDS involves substantial costs to the Swiss MHI. Substitution of iron sucrose 
with ferric carboxymaltose may help to reduce these due to reduced personnel costs. 
This novel type of real-life BIA will be of increasing interest as conditional reimburse-
ment increases.
PSY13
COST IMPACT FROM INITIATING PREGABALIN TREATMENT IN 
PATIENTS WITH REFRACTORY NEUROPATHIC PAIN
Myrén KJ1, Löfroth E1, Sandelin R2
1IMS Health, Stockholm, Sweden; 2Pﬁ zer, Sollentuna, Sweden
OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after 
initiation of pregabalin in difﬁ cult-to-treat neuropathic pain (NeP) patients. 
METHODS: This was a retrospective longitudinal database study in NeP patients 
from the South-West region of Sweden (1.5 million inhabitants). Individual patient 
data from the 1st of January 2000 on health care visits (outpatient, inpatient, primary 
care), costs, mortality and diagnoses were included. Data from the Swedish Prescribed 
Drug register were included from July 1, 2005 until December 31, 2007. Difﬁ cult-to-
treat NeP was deﬁ ned as patients with a NeP diagnosis in 2006, who had had 2 
prescriptions of at least three pain medications during one year from the index diag-
nosis date. The patients should also have had two or more prescriptions of pregabalin 
preceded by at least a six months pregabalin naïve period. RESULTS: A total of 462 
difﬁ cult-to-treat NeP patients met the above criteria and were included in the analyses. 
There was a statistically signiﬁ cant reduction in NeP related costs (visits registered 
with a NeP diagnosis) after initiation of pregabalin (p = 0.0042 Mann-Whitney). The 
mean per patient NeP related costs were SEK17,684 (c1,845) 6 months before and 
SEK10,642 (c1,110) 6 months after pregabalin initiation. The mean non-NeP related 
costs before treatment (SEK46,095; c4,809) did not differ signiﬁ cantly from the 
non-NeP costs after treatment (SEK 51,632; c5,387), p = 0.8016. The number of 
NeP-related in-patient visits, primary care visits and the number of days in hospital 
decreased signiﬁ cantly (p = 0.0475, p = 0.0129, p = 0.0179, respectively) after treat-
ment with pregabalin. CONCLUSIONS: Initiation of pregabalin signiﬁ cantly reduced 
the NeP related health care costs in the 6-month period following initiation. Of note 
was the non signiﬁ cant difference in non-NeP related costs, probably reﬂ ecting the 
on-going costs associated with management of the patients’ concurrent conditions, eg, 
diabetes.
PSY14
REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN: 
TREATMENT PATTERN AND COSTS
Ivanova JI1, Birnbaum HG2, Kantor E2, Schiller M2, Swindle R3
1Analysis Group, Inc., New York, NY, USA; 2Analysis Group, Inc., Boston, MA, USA; 3Eli Lilly 
& Company, Indianapolis, IN, USA
OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for 
chronic low back pain (CLBP). METHODS: Study sample was selected from a U.S. 
privately-insured claims database (2004–2008). Selection criteria: ages 18–64 years, 
had a low back pain (LBP) diagnosis (per HEDIS speciﬁ cations) with a subsequent 
CLBP-qualifying diagnosis recorded 90 days or more after the initial LBP diagnosis. 
Duloxetine-treated patients had ≥1 duloxetine prescription within 6 months after 
CLBP diagnosis, no prior duloxetine claim, and continuous eligibility ≥12 months 
before ﬁ rst LBP diagnosis and ≥6 months after index duloxetine prescription (study 
period). 553 duloxetine-treated patients were matched to a total of 553 control 
patients who initiated another non-surgical LBP treatment based on propensity score 
and time from ﬁ rst LBP diagnosis to treatment initiation. a subset (n = 103 each) of 
matched employees was also analyzed. McNemar tests were used to compare LBP 
treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and 
drug) costs from third-party payer perspective and employee indirect (workloss) costs. 
RESULTS: During the 6-month study period, matched duloxetine-treated patients had 
signiﬁ cantly lower rates of other pharmacological therapy than controls (e.g., 56.2% 
vs. 64.9% narcotic opioids, p = 0.002; 34.9% vs. 49.5% NSAIDs; P < 0.001) and 
non-invasive therapy (28.8% vs. 38.5% chiropractic therapy; 25.5% vs. 35.4% physi-
cal therapy; 17.5% vs. 28.4% exercise therapy; all P < 0.001). Duloxetine-treated 
patients versus controls had numerically lower back surgery rates (2.2% vs. 3.8%, p 
= 0.117) and similar direct costs ($7658 vs. $7439, p = 0.812). Among CLBP employ-
ees, duloxetine-treated employees versus controls had lower rates of other non-surgical 
therapy, numerically lower back surgery rates (0% vs. 3.9%, p = 0.125), lower total 
direct and indirect costs ($5227 vs. $7229, p = 0.042), and numerically lower indirect 
costs ($1806 vs. $2664, p = 0.053). CONCLUSIONS: Duloxetine treatment in CLBP 
patients/employees versus other non-surgical treatment was associated with reduced 
rates of non-surgical therapies and numerically lower surgery rates without increased 
costs.
PSY15
CONSTIPATION RELATED TO OPIOID THERAPY: A COST-OF-ILLNESS 
AND PREVALENCE DATABASE STUDY IN THE BRAZILIAN PRIVATE 
SETTING
Takemoto ML1, Fernandes RA1, Passos RB1, Colombini-Netto M2, Bertola-Neto A2, 
Almeida GR3, Monteiro R3
1ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2Axismed Gestão Preventiva da 
Saúde, São Paulo, SP, Brazil; 3Pﬁ zer, São Paulo, SP, Brazil
OBJECTIVES: To estimate the prevalence of constipation concomitant to opioid 
treatment and related resource utilization and costs from the private payer perspective. 
METHODS: Patients on opioid therapy were identiﬁ ed from a longitudinal insurance 
claims database consisting in 1,057,033 individuals for a period of 35 months. An 
algorithm was used to identify patients on opioid therapy with coincident constipa-
tion-related claims according to ICD-10 codes, targeted procedures and opioid use 
criteria. Resource utilization and costs were determined for these individuals and 
compared with patients on opioid therapy without constipation, without opioid 
therapy with constipation and without both conditions. Results were compared using 
ANOVA with a signiﬁ cance level of 0.05 and are presented per individual per month. 
RESULTS: A total of 23,313 patients were classiﬁ ed as opioid treated patients (2.21% 
of total population) and 6,678 had events related to constipation (29.03% of the 
opioid population). Compared with opioid treated patients without constipation, 
incremental mean total costs per month per patients with the condition were 261.18 
BRL (P < 0.001). The average cost per month for opioid-related constipation patients 
was 787.84 BRL, signiﬁ cantly higher than patients on opioid therapy without consti-
pation (526.66 BRL), with no opioid therapy but constipated (284.47 BRL) and 
without both (90.17 BRL) (P < 0.001 for all comparisons). Patients with claims related 
to both conditions had signiﬁ cantly more days in hospital per month (0.25 vs. 0.497, 
P < 0.001), outpatient ofﬁ ce visits (1.04 vs. 1.59, P < 0.001), outpatient procedures 
(4.69 vs. 14.05, P < 0.001) and tests and therapies (31.95 vs. 36.66, P < 0.001) than 
did patients without opioid-related constipation claims. CONCLUSIONS: The eco-
nomic burden of patients with constipation events coincident with opioid treatment 
is signiﬁ cantly higher when compared to all other groups. Constipated patients 
without opioid therapy had also higher costs than those free of both conditions. These 
results indicate that reducing opioid-induced constipation has potential cost savings 
for the health care system.
PSY16
CHANGES IN SELF-REPORTED PAIN SCORES ASSOCIATED WITH 
DULOXETINE VERSUS OTHER ANTIDEPRESSANTS AMONG PATIENTS 
WITH MAJOR DEPRESSIVE DISORDER IN THE UNITED STATES 
VETERANS AFFAIRS HEALTH CARE NETWORK
Liu J1, Zhao Y2, Happich M3, Shi L1
1Tulane University, New Orleans, LA, USA; 2Eli Lilly & Company, Indianapolis, IN, USA; 3Eli 
Lilly & Company, Windlesham, UK
OBJECTIVES: This study compared self-reported pain scores among patients with 
major depressive disorder (MDD) in the U.S. Veterans Affairs (VA) health system 
treated with duloxetine versus other antidepressants. METHODS: The electronic 
medical records between October 1, 2004 and October 31, 2008 were obtained from 
the VA Veterans Integrated Service Network 16 data warehouse. All patients treated 
with either duloxetine monotherapy or other antidepressants (non-duloxetine) were 
selected. The ﬁ rst dispense date of the index agent was deﬁ ned as the index date. All 
patients must have: 1) 1 + prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3); 2) no 
prior diabetes (ICD-9-CM: 250.xx) or bipolar (ICD-9-CM: 296.4x-296.8x) diagnosis; 
and 3) self-reported pain score measured within 60 days both before the index date 
(baseline pain score) and after the last dispense date of the index antidepressants 
during the 12-month post-index period. The non-duloxetine-treated patients were 
matched to the duloxetine-treated patients via propensity scoring (1:1 ratio), control-
ling for demographics, comorbidities, prior opioid use, prior health care utilization, 
and baseline pain scores. Opioid utilization and pain scores over the 12-month post-
index period were examined between cohorts. RESULTS: The study sample included 
210 duloxetine- and 210 non-duloxetine-treated patients. Signiﬁ cantly less duloxetine-
treated patients than non-duloxetine-treated patients used opioids (20.1%; vs. 34.3%, 
p = .002) over the 12-month post-index period. Both cohorts had similar morphine-
equivalent opioid daily use and pain scores during the follow-up period. Controlling 
for baseline pain scores and medication duration, duloxetine-treated patients had 1.58 
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points (p = 0.007) lower pain score than non-duloxetine-treated patients among 
individuals who had any opioid use during the 12-month post-index period. CON-
CLUSIONS: Among similar VA patients with MDD, patients treated with duloxetine 
were associated with lower opioid use than those treated with other antidepressants. 
Among individuals with any opioid use over the 12-month post-index period, duloxetine-
treated patients had better pain scores than non-duloxetine-treated patients.
PSY17
ECONOMIC OUTCOMES ASSOCIATED WITH HYDROXYUREA 
ADHERENCE AMONG PEDIATRIC MEDICAID ENROLLEES WITH SICKLE 
CELL DISEASE
Candrilli S1, O’Brien SH2, Balkrishnan R3
1RTI Health Solutions, Research Triangle Park, NC, USA; 2The Research Institute at 
Nationwide Children’s Hospital, Columbus, OH, USA; 3University of Michigan, College of 
Pharmacy, Ann Arbor, MI, USA
OBJECTIVES: Although not approved for use in pediatrics, hydroxyurea has been 
shown to decrease painful vaso-occlusive events and hospitalizations (HU) in children 
with sickle cell disease (SCD), a genetic hematologic disorder primarily affecting 
people of African descent. However, few data exist on the use of HU, and adherence 
to treatment, in real-world settings. This study assessed the extent to which children 
with SCD are adherent with prescribed HU therapy and the association between HU 
adherence and economic outcomes in this population in a real-world setting. 
METHODS: Insurance claims of North Carolina Medicaid program enrollees (June 
1999-August 2008) were analyzed. Inclusion criteria were ≥1 claims with a diagnosis 
for SCD (i.e., ICD-9-CM 282.6, 282.6x), ≥2 HU prescriptions in the year following 
HU initiation, ≤18 years old at the time of HU initiation, and continuous Medicaid 
enrollment for ≥12 months prior to and following HU initiation. Adherence was 
measured using the medication possession ratio (MPR), with MPR > 0.8 considered 
adherent. Multivariable models were estimated to assess the association between HU 
adherence and economic outcomes (e.g., inpatient costs) in the ﬁ rst year of HU therapy. 
RESULTS: A totla of 159 subjects (55% female, mean age [SD] 11.3 [4.4] years) met all 
inclusion criteria. The mean MPR was 0.63, with 41% of subjects adherent. Multivariable 
models revealed that in the year following HU initiation, adherence was associated with 
a reduction in all-cause (-$3.695, p = 0.0003) and SCD-related (-$3.002, P < 0.0001) 
total, inpatient (-$2172, p = 0.001; -$1815, P < 0.0001, respectively), ER (-$314, P < 
0.0001; -$202, p = 0.002, respectively), outpatient (-$951, P < 0.0001; -$541, p = 0.005, 
respectively), and vaso-occlusive event-related (-$3639, P < 0.0001) costs, and an increase 
in all-cause (+$239, p = 0.014) and SCD-related pharmacy (+$198, P < 0.0001) costs. 
CONCLUSIONS: Adherence to HU among pediatric SCD patients may be suboptimal 
and improving adherence to HU therapy among these patients may reduce the eco-
nomic burden of the illness.
PSY18
DIRECT MEDICAL COSTS OF LIQUID INTRAVENOUS 
IMMUNOGLOBULINS IN CHILDREN, ADOLESCENTS AND ADULTS IN 
SPAIN
Darba J1, Restovic G2, Kaskens L2, de Agustin T3
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain; 3CSL Behring, 
Esplugues de Llobregat, Spain
OBJECTIVES: The aim of this study is to determine health care resource utilization 
and direct medical costs in patients treated with intravenous immunoglobulins (IVIGs) 
in Spain in 2009. METHODS: A cost-of-illness analyses was performed to estimate 
direct medical annual costs of patients treated with IVIGs. Prevalence data was 
obtained from the Spanish Primary Immunodeﬁ ciency registry. a semi-structured ques-
tionnaire was used to collect data on health care resource utilization and target popula-
tion distribution. Inpatient and outpatient costs were considered from the perspective 
of the public health care system. Hospital costs considered were ambulatory-, ward-, 
premedication-, drug- and administration costs. All costs referred to 2009. In medical 
practice, IVIG doses depend on a patient’s weight and age. Therefore separate analyses 
were conducted for children and adolescents vs. adults. RESULTS: Patients with 
replacement therapy were estimated to be 4192 (724 children and adolescents vs. 3450 
adults) for 2009. Patients with immunomodulation were estimated to be 1378 (244 
children and adolescents vs. 1134 adults) and patients with an allogeneic bone marrow 
transplantation were estimated at 172 (30 children and adolescents vs. 142 adults ). 
Mean annual costs for children and adolescents were c6283 with Privigen, c6292 with 
Kiovig, c6946 with Flebogamma and c6559 with Octagamocta. For adults estimations 
were c17,078 with Privigen, c17,103 with Kiovig, c18,095 with Flebogamma and 
c17,423 with Octagamocta. CONCLUSIONS: Direct medical costs for IVIGs were 
estimated to be c6.9 million for children and adolescents and c84.8 million for adult 
patients. Drug costs represented 94% of the total direct medical costs. In the context 
of limited health care resources, the choice for a certain IVIG treatment depends on 
individual patient characteristics and cost considerations.
PSY19
PREDICTORS OF DULOXETINE TREATMENT INITIATION AMONG 
PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN IN 
SOUTH CENTER VETERANS AFFAIRS HEALTH CARE NETWORK IN 
THE UNITED STATES
Shi L1, Liu J1, Zhao Y1, Zhao Y2
1Tulane University, New Orleans, LA, USA; 2Eli Lilly & Company, Indianapolis, IN, USA
OBJECTIVES: To explore predictors of duloxetine initiation versus other standard of 
care (SOC) treatments for patients with diabetic peripheral neuropathic pain (DPNP) 
in the Veterans Affairs (VA) health system. Duloxetine was not on the VA national 
drug formulary. METHODS: The electronic medical records from January 2004 to 
December 2008 were requested from the Veterans Integrated Service Network 16 data 
warehouse. All patients selected initiated either duloxetine or SOC (tricyclic antide-
pressants [TCAs], venlafaxine, gabapentin, pregabalin) over the study period, with the 
ﬁ rst dispense date of the index agent as the index date. All patients must have at least 
1 prior DPNP diagnosis (ICD-9-CM: 250.6x or 357.2), but no prior depression (ICD-
9-CM: 296.2, 296.3, 300.4, 309.1, 311.0), ﬁ bromyalgia (ICD-9-CM: 729.1), or 
neuralgia (ICD-9-CM: 729.2) diagnosis. Logistic regressions were used to examine the 
predictors of initiating duloxetine versus SOC controlling for demographics, comor-
bidities, prior pain level, and prior SOC or opioid use. RESULTS: The analytical 
sample included 2675 (215 duloxetine and 2460 SOC) patients. Prior use of gabap-
entin (odds ratio [OR] = 13.66, 95% conﬁ dence interval [CI]: 9.70–19.24, TCAs (OR 
= 5.40, 95% CI: 3.73–7.82), or venlafaxine (OR = 3.67, 95% CI: 1.67–8.06) was 
strongly associated with duloxetine initiation. Patients comorbid with anxiety, cere-
brovascular disease, or substance abuse were 1.08 (95% CI: 1.40–3.08), 0.44 (95% 
CI: 1.01–2.07), and 1.11 (95% CI: 1.10–4.03) times more likely to initiate duloxetine, 
respectively. Prior opioid users were 1.47 (95% CI: 1.02–2.12) times as likely to initi-
ate duloxetine as those with no prior opioid use. Patients with self-reported severe 
pain were 1.66 (95% CI: 1.11–2.50) times as likely to initiate duloxetine as those with 
no reported pain. CONCLUSIONS: DPNP patients in the VA health care system who 
initiated duloxetine appeared to have prior SOC use, more comorbid conditions, prior 
substance abuse or opioid use, and higher pain level.
PSY20
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS COSTLY FOR THE 
HEALTH CARE SYSTEM AND WORKPLACE: A SYSTEMATIC 
LITERATURE REVIEW
Doria A1, Grandﬁ ls N2, Maurel F2, Rudge H3
1University of Padova, Padova, Italy; 2IMS Health, Paris, France; 3GlaxoSmithKline, Uxbridge, 
Middlesex, UK
OBJECTIVES: To summarise the state of knowledge of the economic impact of SLE 
and to gather information to implement a European study on costs of SLE care. 
METHODS: A systematic review of the literature was undertaken in the ECONLIT, 
EMBASE, Medline and EMBR databases for full papers relating to the objectives. Key 
words included SLE, cost, resource, economic, productivity, absenteeism, employment 
and work disability. Papers were excluded if they were not in English, French, Spanish, 
Italian or German language. RESULTS: Thirty relevant research papers (relating to 
13 different studies) were included. These studies were conducted in Canada, China, 
Germany, UK and US and used retrospective and prospective methods. Data were 
mainly obtained from the hospital care setting over a one-year study period. The main 
resources reported were physician and emergency visits, as well as inpatient hospital 
stays (of which SLE ﬂ ares and infections were the main causes). Annual direct costs 
(converted to December 2009 Euros) ranged from c2,879 (Canada) to c14,873 (US), 
with indirect costs of c1,214 (US/UK/Canada, friction method) to c45,668 (US, labour 
market activity method). Indirect costs accounted for at least 38% of the total costs 
when both market and non-market work was valued. Higher disease activity was 
reported as a predictor of higher direct and indirect costs. Greater damage, more ﬂ ares 
and nephritis were also found to predict higher direct costs whilst worse physical and/
or mental status predicted higher indirect costs. Only one study focussed on the cost 
of ﬂ ares. CONCLUSIONS: SLE is costly for the health care system and workplace. 
However, there is a lack of data on the cost of SLE ﬂ ares and little recent European 
data relating to the cost of SLE care. HGS/GSK funded.
PSY21
THE IMPACT OF COMORBIDITY ON INFLAMMATORY BOWEL DISEASE 
HEALTH COSTS
Lepore V1, D’Ettorre A1, Graziano G1, Martinelli D2, Tafuri S3, Tognoni G1
1Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy; 2Apulia Regional 
Epidemiological Observatory, Foggia, Italy; 3Apulia Regional Epidemiological Observatory, 
Bari, Italy
OBJECTIVES: To quantify the direct costs (hospitalizations and prescription drugs) 
of the caring strategies for the Inﬂ ammatory Bowel Disease (IBD). METHODS: All 
cases of the major types of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), 
occurred in Apulia between 2002 and 2006 were in the study. The patients were 
identiﬁ ed through a record linkage procedure among three different regional health 
databases. Multivariate Poisson regression accounting for over-dispersion was used to 
assess the average annual direct costs per person. Results were reported, separately 
for the two diseases, as Incidence Rate Ratios (IRR) with 95% conﬁ dence intervals. 
RESULTS: The cohort consisted of 2,700 cases of CD and 4902 cases of UC. We 
estimated the average annual costs per person in patients with CD to be equal to 7,153 
Euros for hospitalizations and to c2107 for prescription drugs. In patients with UC 
the average annual costs per person was of c6317 and c2277 for hospitalizations and 
prescription drugs, respectively. Surgical to medical DRGs ratio for both diseases was 
1:5 and the ATC codes relative to intestinal anti-inﬂ ammatory, proton pump inhibi-
tion, anti-inﬂ ammatory/anti-rheumatic and corticosteroids products, represented the 
40% of all prescriptions. Overall, the analyses showed, both for DC and CU, that the 
Charlson Comorbidity Index (CCI) was the only variable associated with the direct 
costs i.e. a signiﬁ cant increase in the costs (p-value < 0.0001) was found according to 
the severity of the CCI. In particular, it was noted that a worse clinical condition 
before disease onset (CCI before index date) was predictive of larger costs especially 
